Announcements Trials
Browse Landscape

Status

Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 18Observational 4Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 3

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Myeloid, Chronic-Phase 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Observational × asciminib × Clear all
NCT06092879 2026-05-29

ASSURE-3

Novartis

Active not recruiting
201 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05943522 2026-04-20

Asciminib RMP Study

Novartis

Recruiting
600 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07091019 2025-07-29

ASC4REAL-2

Novartis

Not yet recruiting
1,000 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT05421091 2024-03-27

Special Drug Use-results Surveillance of Scemblix Tablets

Novartis

Completed
550 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡